1
|
Abstract
Abstract
Purpose of review
As fields such as neurotoxicity evaluation and neuro-related drug research are increasing in popularity, there is a demand for the expansion of neurotoxicity research. Currently, neurotoxicity is assessed by measuring changes in weight and behavior. However, measurement of such changes does not allow the detection of subtle and inconspicuous neurotoxicity. In this review, methods for advancing neurotoxicity research are divided into molecule-, cell-, circuit-, and animal model-based methods, and the results of previous studies assessing neurotoxicity are provided and discussed.
Recent findings
In coming decades, cooperation between universities, national research institutes, industrial research institutes, governments, and the private sector will become necessary when identifying alternative methods for neurotoxicity evaluation, which is a current goal related to improving neurotoxicity assessment and an appropriate approach to neurotoxicity prediction. Many methods for measuring neurotoxicity in the field of neuroscience have recently been reported. This paper classifies the supplementary and complementary experimental measures for evaluating neurotoxicity.
Collapse
|
2
|
Chambers C, Witton I, Adams C, Marrington L, Kammonen J. High-Throughput Screening of NaV1.7 Modulators Using a Giga-Seal Automated Patch Clamp Instrument. Assay Drug Dev Technol 2016; 14:93-108. [DOI: 10.1089/adt.2016.700] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Affiliation(s)
- Chris Chambers
- Neuroscience and Pain Research Unit, Pfizer Inc., Cambridge, United Kingdom
| | - Ian Witton
- Neuroscience and Pain Research Unit, Pfizer Inc., Cambridge, United Kingdom
| | - Cathryn Adams
- Neuroscience and Pain Research Unit, Pfizer Inc., Cambridge, United Kingdom
| | - Luke Marrington
- Neuroscience and Pain Research Unit, Pfizer Inc., Cambridge, United Kingdom
| | - Juha Kammonen
- Neuroscience and Pain Research Unit, Pfizer Inc., Cambridge, United Kingdom
| |
Collapse
|
3
|
Hao Y, Tang J, Wang K. Development of Automated Patch Clamp Assay for Evaluation of α7 Nicotinic Acetylcholine Receptor Agonists in Automated QPatch-16. Assay Drug Dev Technol 2015; 13:174-84. [PMID: 25880723 DOI: 10.1089/adt.2014.622] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The α7 nicotinic acetylcholine receptor (α7 nAChR) is an important and challenging target for drug discovery in the area of neuropsychiatric disorders. The current screening for chemicals targeting α7 nAChRs is primarily achieved by the use of low-throughput assay two-electrode voltage clamp (TEVC) in nonmammalian Xenopus oocytes. Automated patch clamp system has emerged as an attractive approach compared to conventional electrophysiology. To develop a mammalian cell-based functional assay in an automated electrophysiology system, we in this study generated a stable expression of α7 nAChRs in GH3 cells that originated from a rat pituitary tumor cell line and utilized automated QPatch-16 to test a set of tool compounds and chemicals identified as α7 agonists by TEVC. For the improvement of evaluating weak or partial α7 nAChRs agonists, we achieved enhancement of the signal-to-noise ratio by the addition of a positive allosteric modulator PNU-120596, which only activates α7 current in the presence of agonist. This improved assay was further validated by using known α7 partial agonists, such as RG3487, EVP-6124, and A-P90. Using this validated assay, we were able to identify a novel agonist 140507C that partially activates α7 nAChRs. Taken together, our results validate the use of QPatch-16 for evaluation α7 partial agonists, demonstrating its utility as an effective tool for α7 ion channel drug discovery.
Collapse
Affiliation(s)
- Yuchen Hao
- 1 Department of Molecular and Cellular Pharmacology, State Key Laboratory of Natural and Biomimetic Drugs, Peking University School of Pharmaceutical Sciences , Beijing, China
| | | | | |
Collapse
|
4
|
Bill A, Popa MO, van Diepen MT, Gutierrez A, Lilley S, Velkova M, Acheson K, Choudhury H, Renaud NA, Auld DS, Gosling M, Groot-Kormelink PJ, Gaither LA. Variomics screen identifies the re-entrant loop of the calcium-activated chloride channel ANO1 that facilitates channel activation. J Biol Chem 2014; 290:889-903. [PMID: 25425649 DOI: 10.1074/jbc.m114.618140] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
The calcium-activated chloride channel ANO1 regulates multiple physiological processes. However, little is known about the mechanism of channel gating and regulation of ANO1 activity. Using a high-throughput, random mutagenesis-based variomics screen, we generated and functionally characterized ∼6000 ANO1 mutants and identified novel mutations that affected channel activity, intracellular trafficking, or localization of ANO1. Mutations such as S741T increased ANO1 calcium sensitivity and rendered ANO1 calcium gating voltage-independent, demonstrating a critical role of the re-entrant loop in coupling calcium and voltage sensitivity of ANO1 and hence in regulating ANO1 activation. Our data present the first unbiased and comprehensive study of the structure-function relationship of ANO1. The novel ANO1 mutants reported have diverse functional characteristics, providing new tools to study ANO1 function in biological systems, paving the path for a better understanding of the function of ANO1 and its role in health and diseases.
Collapse
Affiliation(s)
- Anke Bill
- From the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139
| | - M Oana Popa
- the Novartis Institutes for Biomedical Research, Horsham, West Sussex RH12 5AB, United Kingdom, and
| | - Michiel T van Diepen
- the Novartis Institutes for Biomedical Research, Horsham, West Sussex RH12 5AB, United Kingdom, and
| | - Abraham Gutierrez
- From the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139
| | - Sarah Lilley
- the Novartis Institutes for Biomedical Research, Horsham, West Sussex RH12 5AB, United Kingdom, and
| | - Maria Velkova
- the Novartis Institutes for Biomedical Research, Horsham, West Sussex RH12 5AB, United Kingdom, and
| | - Kathryn Acheson
- the Novartis Institutes for Biomedical Research, Horsham, West Sussex RH12 5AB, United Kingdom, and
| | - Hedaythul Choudhury
- the Novartis Institutes for Biomedical Research, Horsham, West Sussex RH12 5AB, United Kingdom, and
| | - Nicole A Renaud
- From the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139
| | - Douglas S Auld
- From the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139
| | - Martin Gosling
- the Novartis Institutes for Biomedical Research, Horsham, West Sussex RH12 5AB, United Kingdom, and
| | | | - L Alex Gaither
- From the Novartis Institutes for Biomedical Research, Cambridge, Massachusetts 02139,
| |
Collapse
|